

Synthesis and preclinical investigation of lactosamine-based radiopharmaceuticals for the detection of galectin-3-expressing melanoma cells

Barbara Gyuricza, Ágnes Szűcs, Judit P. Szabó, Viktória Arató, Zita Képes, Dániel Szücs, Dezső Szikra, György Trencsényi, Anikó Fekete

Part 1: ^1H NMR and ^{13}C NMR spectra of compound 2, 3 and 4.




Figure S1 ^1H NMR spectrum of compound 2




Figure S2 ^{13}C NMR spectrum of compound 2




Figure S3 ¹H NMR spectrum of compound 3




Figure S4 ¹³C NMR spectrum of compound 3




Figure S5 ^1H NMR spectrum of compound 4

Part 2: Mass spectra of compound 2, 3, 4, 7, 8 and 9






Figure S6 Mass spectrum of compound 2

**Figure S7** Mass spectrum of compound 3**Figure S8** Mass spectrum of compound 4




Figure S9 Mass spectrum of compound 7




Figure S10 Mass spectrum of compound 8




Figure S11 Mass spectrum of compound 9

Part 3: Stability studies of $[^{68}\text{Ga}]\text{Ga-DOTAGA-LacN(NAP)}$ and $[^{68}\text{Ga}]\text{Ga-DOTAGA-LacN(NAP)-cRGDfK}$




Figure S12 Stability test of $[^{68}\text{Ga}]\text{Ga-DOTAGA-LacN(NAP)}$ in 0.01 M Na_2EDTA solution.




Figure S13 Stability test of [^{68}Ga]Ga-DOTAGA-LacN(NAP) in 0.01 M oxalic acid solution.




Figure S14 Stability test of [^{68}Ga]Ga-DOTAGA-LacN(NAP)-cRGDfK in 0.01 M Na_2EDTA solution.




Figure S15 Stability test of [⁶⁸Ga]Ga-DOTAGA-LacN(NAP)-cRGDfK in 0.01 M oxalic acid solution.




Figure S16 Radio-TLC chromatogram of [⁶⁸Ga]GaCl₃ solution.




Figure S17 Stability test of [⁶⁸Ga]Ga-DOTAGA-LacN(NAP) in human serum after 2 hours.




Figure S18 Stability test of [⁶⁸Ga]Ga-DOTAGA-LacN(NAP)-cRGDfK in human serum after 2 hours.

TableS1 *Ex vivo* biodistribution of ^{68}Ga -labeled DOTAGA-LacN(NAP), DOTAGA-LacN(NAP)-cRGDfK, and DOTAGA-cRGDfK in B16-F10 tumor-bearing mice (n=5/radiopharmaceutical) 100 min after intravenous injection of the radiotracers. %ID/g tissue values are presented as mean \pm SD.

	[^{68}Ga]Ga-DOTAGA- LacN(NAP)	[^{68}Ga]Ga-DOTAGA- LacN(NAP)-cRGDfK	[^{68}Ga]Ga-DOTAGA- cRGDfK
blood	0.29 \pm 0.01	0.58 \pm 0.14	0.37 \pm 0.05
liver	0.33 \pm 0.19	2.19 \pm 0.73	1.00 \pm 0.25
spleen	0.17 \pm 0.02	1.60 \pm 1.17	0.80 \pm 0.09
kidney	8.19 \pm 1.36	6.14 \pm 1.14	2.43 \pm 0.26
small intestine	0.27 \pm 0.9	1.77 \pm 0.96	0.78 \pm 0.20
large intestine	0.13 \pm 0.01	1.74 \pm 0.70	0.55 \pm 0.16
stomach	0.14 \pm 0.04	1.70 \pm 0.72	0.69 \pm 0.21
muscle	0.05 \pm 0.01	0.27 \pm 0.07	0.10 \pm 0.01
fat	0.11 \pm 0.08	0.17 \pm 0.13	0.19 \pm 0.08
lungs	0.35 \pm 0.06	1.54 \pm 0.62	0.66 \pm 0.18
heart	0.12 \pm 0.02	0.61 \pm 0.17	0.26 \pm 0.06
brain	0.02 \pm 0.01	0.06 \pm 0.01	0.03 \pm 0.01
bone (femur)	0.07 \pm 0.02	0.54 \pm 0.21	0.26 \pm 0.04
salivary glands	0.11 \pm 0.02	1.34 \pm 0.50	0.54 \pm 0.18
gall bladder	0.43 \pm 0.38	3.07 \pm 2.10	0.84 \pm 0.29
pancreas	0.11 \pm 0.06	0.43 \pm 0.12	0.18 \pm 0.06